The Record Is Large Enough to Disagree

Mindmax

Interrupting the teacher is part of the lesson at Mindmax. The question you were embarrassed to ask in a room full of people gets to change what happens next.

Ed Cooke and Daniel Zohar are building around that permission. Their conversational AI tutor helps adults prepare for professional exams and build skills, adjusting the lesson as the learner answers, asks for another explanation or admits the previous one went straight past them.

Concept Ventures led Mindmax's $3.3M round, announced November 5, 2026, with Redrice Ventures, Daybreak Ventures and Lerer Hippeau participating. Maria Raga, former CEO of Depop, and Torsten Reil, co-founder of Helsing, joined as angels. That puts experienced consumer and technology investors behind a product asking people to stay mentally involved.

Cooke co-founded Memrise, where Zohar worked alongside him as CTO. They have already spent years dealing with the distance between material someone has seen and knowledge someone can actually use. Mindmax carries that experience into a conversation that can follow the learner's confusion instead of making the learner keep up with a fixed recording. That makes the return visit part of the teaching brief. The app has to remember where an explanation failed and give that learner a reason to reopen it.

The product combines spoken lessons with visual explanations. Its learning coach plans short daily sessions around a goal and checks in when the learner goes quiet. There is a useful commercial detail hiding in that last job: a professional qualification comes with a deadline, but studying still has to survive ordinary life.

Concept reports thousands of people already using Mindmax for professional exams. Those are reported users, without a disclosed pass-rate study attached. Cooke told Tech Funding News the money will support growth and technology development; the same interview describes expert content review and technical checks, with no published error rates.

For this category, the moment of hesitation deserves serious product attention. A tutor has to decide whether to explain again, ask another question or leave enough space for the learner to work. A fluent voice can make that encounter comfortable. The instruction has to make the next attempt more useful.

The founders now have more backing to develop those decisions across different subjects and people. Somewhere inside that work is the adult who needs to ask the same question a third time, then return tomorrow with enough confidence to try the answer alone.

Fact Base

A factory with 12 employees can be a serious software customer. The product has to earn a place in a working day, and the person running the shop has to be able to approve the bill.

That buying authority sits inside Fact Base's growth story. Founder and CEO Masataka Takeuchi built the Japanese manufacturing software company around ZUMEN, a cloud platform that connects technical drawings with the quotations, instructions and documents needed to put them to work. The drawing becomes the place to recover a job’s context.

A drawing arrives before an order does. Somebody has to find related work, recover useful information and decide what the job should cost. Software that starts only after the purchase order misses the work that helps a small factory win it.

MPower Partners makes that commercial argument in explaining its new investment. It says Fact Base priced ZUMEN within reach of small factories and built a disciplined sales approach from time spent visiting them. For a company serving modest accounts, knowing how to reach the buyer is part of the product economics.

On November 5, Fact Base announced a ¥4.5B Series D package led by returning investor Insight Partners, with Artemis Ventures and MPower Partners joining. The package combines newly issued shares and secondary share sales; the split was undisclosed, so the full ¥4.5B cannot be treated as fresh cash entering the business.

The company reports revenue growing 2.3 times year over year, customer-company count growing 2.2 times, and a footprint spanning 14 countries. Those are company-reported figures. Its cumulative funding figure is ¥11.25B.

The drawing gives Fact Base a familiar starting point abroad. A manufacturer in another country also needs to retrieve the history behind a job. The sales conversation, customer support and local organization still need people who understand the market they are entering.

Fact Base plans to expand overseas hiring and sales, develop ZUMEN, add new businesses and strengthen governance. That last item belongs in the story: running an international software company means making local growth manageable from the center while keeping decisions close enough to the customer.

Takeuchi's ambition extends into quoting, ordering, production and procurement. The useful expansion path follows information the factory already trusts, giving the next department a reason to use the same drawing and the next small customer a reason to take the meeting.

Dronamics

Hellmann is planning freight capacity before Dronamics has begun commercial revenue operations. That puts a practical question inside a proposed Nasdaq listing: how does a promising aircraft become a service a forwarder can put on a customer's schedule?

Dronamics wants to build the aircraft and operate the flights. Its Black Swan is designed to carry up to 350 kg over 2,500 km, using regional airfields to move cargo between places that can be awkward to connect quickly by road. The specifications come from the company. The buyer needs dependable capacity attached to them.

Svilen Rangelov, co-founder and president, and Konstantin Rangelov, co-founder and CTO, started Dronamics in 2014. The current transaction presentation names Zornitsa Yanakieva as CEO. Their next assignment spans manufacturing, flight operations and several different customers for the same underlying platform.

GP-Act III Acquisition Corp., led by CEO Antonio Bonchristiano, has agreed to combine with the Sofia-based company. The agreement was signed November 3. The proposed deal puts Dronamics at $400M in pre-money equity value and approximately $500M in pro forma enterprise value. Existing shareholders are expected to roll over 100% of their equity.

The financing plan targets about $100M in net cash at closing, subject to shareholder redemptions and PIPE commitments. The contractual minimum is $25M net. Those figures describe different things, and a production plan has to live with the cash that actually arrives. Closing is expected in the first half of 2027, subject to approvals and other conditions.

Hellmann's cooperation agreement is binding, but committed volumes and pricing are set market by market as routes launch. Dronamics' wider cargo pipeline includes nonbinding arrangements. A forwarder's interest gives the aircraft a commercial destination; agreeing the route, price and repeat schedule gives the factory something firmer to build around.

The platform is also being developed for defense sensing with HENSOLDT and aerial surveying with Asia Air Survey, which became a strategic investor in April. Different missions can draw on the same engineering, while bringing their own payload integration and operating requirements.

Dronamics is taking that collection of responsibilities toward the public markets. Somewhere between the production line and the regional airfield, the next freight booking will need an aircraft, a permitted flight and a customer ready to use the space.

Ottonomy

A telemetry unit can pull a hospital employee away from the bedside long before it reaches a patient. Picking it up, returning it and finding the next one creates a delivery business inside the hospital's working day.

Ottonomy has built Ottobot around those journeys. On November 4, ENRISSION INDIA CAPITAL announced an investment in the company's pre-Series A through its SP26 India fund. The amount was undisclosed. The Japanese investor is backing a company with a US base and R&D and manufacturing in India, bringing another relationship into a business that has to earn trust building by building.

CEO Ritukar Vijay founded Ottonomy in 2020 with Pradyot Korupolu, Ashish Gupta and Hardik Sharma. Their robots serve healthcare facilities, industrial campuses and parcel delivery. That range makes the route itself a useful way to understand the company: a delivery can pass through a corridor, an elevator, a secured door and an outdoor stretch before anyone receives it.

Ottonomy describes indoor-outdoor navigation, modular compartments and integration with building access systems. Its Contextual AI 2.0 uses vision-language models on Ambarella's N1 edge hardware, according to the company. The engineering reaches into the environment the customer already operates, including the doors that are supposed to stay locked.

Catalyst by Wellstar supplied a particularly useful customer-side account in April 2025. It disclosed its investment in Ottonomy and described a pilot at Wellstar Kennestone Hospital, with a launch then planned for mid-2025. Batteries, lab samples, meals and telemetry equipment were among the jobs it wanted Ottobot to handle. That dated account establishes the work being explored, without supplying a current fleet count or measured time savings.

The hospital is buying room in somebody's day. A robot that carries the equipment still needs a workable pickup, the right destination and a receiving team able to finish the handoff. Those details decide whether automation makes the shift easier or adds another thing staff have to supervise.

ENRISSION's announcement points toward healthcare expansion and software for managing multiple robots. Ottonomy's earlier $3.3M seed in 2022 financed a company pursuing airport, retail and restaurant deliveries. This investment arrives with hospital logistics much closer to the center of its story, where the next useful route has to fit around people who already have patients waiting.

Onvaro

A diagnostics company can spend years learning how to make a test and still need somebody who knows how to get a clinic to buy it. Sapphiros and binx health are putting those two kinds of knowledge inside Onvaro.

The companies announced their completed combination on November 4. Mike Karsonovich will lead Onvaro as CEO, with Sapphiros founder Namal Nawana serving as Lead Director. Funds managed by KKR, through Health Care Strategic Growth, Hildred and EQT Life Sciences are investing new capital. The amount and transaction terms were not disclosed.

binx brings a working commercial proposition. Its io platform delivers molecular chlamydia and gonorrhea results in about 30 minutes, with FDA clearance and a CLIA waiver. The company already sells into clinical settings where the person collecting the sample has an appointment schedule to keep.

That customer needs more than a fast answer. binx's offer includes onboarding, billing support and connections to clinical records. A practice deciding to run testing in-house is also deciding who does the work, where the result goes and how the service gets paid for.

Sapphiros brings technology development and manufacturing, including printed electronics and blood collection. Combining that work with binx's commercial organization gives future products a route toward customers who already have a reason to take the call. Regulatory requirements still apply to the wider pipeline.

There is history behind the pairing. binx announced a $104M Series E in 2021. Its $65M financing package in 2024 included equity, debt and expanded facilities, supporting commercial sales and manufacturing. Those earlier dollars cannot be counted as the price of this combination, or as fresh Onvaro equity.

For the backers, the operating connection is the interesting part. More products could travel through established relationships, while manufacturing sits closer to the organization making the customer promise. Each addition still has to earn its place in the clinic's day. The company can bring the sales conversation and the supply conversation under the same roof, giving the people introducing a test a closer relationship with the people responsible for making it.

Onvaro is also developing a layer intended to connect test results with providers, pharmacies and other care services. That extends Karsonovich's assignment beyond placing an instrument: the result has to keep moving toward someone who can act on it, while the patient is still within reach.

Soter Insure

A stolen Bitcoin can become more expensive to replace while the insurance claim is being processed. For the institution owed that Bitcoin, the currency inside the policy suddenly becomes a very practical design decision.

Soter Insure has built around that decision. Its January announcement described a BTC-denominated crime layer sitting above an exchange's conventional fiat policy. In March, it introduced ETH-denominated slashing cover with Galaxy, aligning premiums and claims with the asset exposed to protocol penalties.

Founder and CEO Henson Orser is bringing more financial institutions into the business behind those contracts. On November 5, Soter announced a second close of its Series B, adding Standard Chartered's SC Ventures and Japan's SBI Group as strategic investors, with Token Bay Capital following on after backing the Series A.

Galaxy leads the round. Coinbase Ventures, Franklin Templeton and Brevan Howard Digital participated in the July first close. The November announcement gives no amount for the additional capital, so there is no honest new-round number to attach to this story.

What the company does identify is the work: more insurance capacity, deeper underwriting and technology capabilities, and expansion across Asia-Pacific through Hong Kong, Europe and the US. Alex Daskalov, CTO/CISO, sits on a team whose product has to connect technical exposure with a contract somebody can actually underwrite.

That combination matters. A staking operator can suffer a penalty in ETH. A custody business can owe assets whose price moved during the claims process. Matching the contract's denomination to the exposure addresses a problem that a reassuring dollar limit can leave inside the customer's balance sheet.

The distribution work is just as concrete. Soter announced a UAE partnership with Dubai Insurance in February, then DFSA insurance-intermediation authorization in May, alongside its Bermuda carrier. More jurisdictions mean more relationships between the people arranging cover and the balance sheet accepting the risk.

SC Ventures and SBI are putting capital behind that less glamorous part of digital finance. Their participation adds institutional networks to a company selling the ability to carry a defined loss. Token Bay's return extends a relationship already running through an earlier round.

As Soter expands, those networks will meet institutions asking which exposures can be covered, in which currency, and on what terms.

Alethio Therapeutics

Adam Mead and Beth Psaila know these blood cancers from both sides of the laboratory door. The Oxford professors treat patients with myeloproliferative neoplasms and study the cells that keep the disease going. Alethio Therapeutics is where those two kinds of knowledge meet a drug-development budget.

The Oxford spin-out announced a $90M Series A on November 5, co-led by Sofinnova Partners and RA Capital. Founding investor Oxford Science Enterprises joined the round, with Cancer Research Horizons and the University of Oxford also supporting it. The early institutions are staying involved as the company prepares to enter clinical development. It launched as Alethiomics in 2021. Beth Psaila is also a board observer.

CEO Rohit Batta is putting the proceeds behind ATX-011, a monoclonal antibody targeting G6B, initially for essential thrombocythaemia. ET involves excessive platelet production and an increased risk of blood clots. Getting those counts under control can occupy a patient's life for years, while the underlying disease continues to demand attention.

Alethio's choice of G6B connects the immediate platelet problem with a wider biological ambition. The company identifies the protein on platelets and megakaryocytes, the cells that make them, and reports abnormal expression on disease-driving MPN stem cells. That gives its researchers a target they believe could reach across different driver mutations.

The financing is intended to carry ATX-011 through Phase 1/2a studies toward Phase 3 readiness, while other MPN programmes advance toward regulatory submissions. ATX-011 remains in IND-enabling work. Disease modification is the ambition being investigated, with human safety and efficacy still to be established.

CSO Ed Ainscow and CDO Steve Coats sit alongside Batta in a team moving from target discovery into development. Behind them is ARTEMIS, Alethio's engine combining patient-derived material, multi-omics, machine learning and organoid models. The company reports target validation in samples from more than 100 MPN patients, a research foundation rather than a clinical treatment result.

Sofinnova's Graziano Seghezzi and RA Capital's Maxwell DeNies are joining the board. Their arrival puts new investors close to the decisions about which experiments, candidates and clinical questions deserve the next commitment of capital. Mead and Psaila's work now has a funded route toward the patients whose disease helped generate it.

bit.bio

A vial of human cells arrives with an experimental question attached. At bit.bio, selling more of those vials increasingly means helping researchers decide how to use them.

The Cambridge company announced a $25M Series D on November 4, with backing including M&G Investments and Jonathan Milner, Abcam's founder and former CEO. The money supports a broader cell portfolio and wider customer access, with manufacturing capacity already established.

CEO Emma Pepperell knows the commercial side of research tools. Before joining bit.bio in 2024, she spent a decade at Abcam. She became CEO in June, after serving as VP Commercial, bringing the customer's buying decision close to the company's operating decisions.

That decision has several moving parts. A research team needs the right cell type, a consistent supply and an experiment it can actually run. A beautiful product specification can still leave a scientist with a substantial amount of work between opening the vial and getting a useful answer.

bit.bio's opti-ox technology programs human stem cells into defined cell types. Founder Mark Kotter remains on the board; Florian Schuster is identified in the company's historical record as a co-founder. Their scientific and commercial project now reaches into the practical business of making those cells usable across more laboratories.

CTO Sejla Salic-Hainzl's remit helps explain the direction. The ioScreen service launched in August lets customers access CRISPR screening in human stem-cell-derived models without assembling the entire specialist operation themselves. Researchers can also bring their own cell models into the service.

That adds another purchasing route, shaped around the expertise a customer already has. Some customers want cells for work they already know how to do. Others need access to experimental capability, giving the supplier a larger role in the research relationship.

The company reports paid vial volumes up 76% year to date, orders up 34% and active customers up 40%. Those measures describe demand from different directions; none is a disclosed revenue-growth figure. M&G also led bit.bio's separate $50M Series C announced in January.

Pepperell's portfolio now includes a myriamed partnership for cardiac cells and ioAstrocytes 2.0 for neuron-astrocyte cultures. Each addition gives a researcher another reason to consider the same supplier when the next biological question calls for a different experiment.

Siggy

Remembering how you slept 3 weeks ago is a strange assignment to give someone already struggling with their mental health. Siggy wants that information to reach the clinician while the week is still happening.

Co-founders Jonathan Sabbagh, CEO, and Edvard Engesaeth, MD, COO, have raised $6M in pre-seed funding led by Village Global. The New York company's November 5 announcement brings together people who have already built healthcare businesses and backers willing to fund them again.

Jonathan Sabbagh co-founded Journey Clinical. Edvard Engesaeth co-founded Nurx and was an early Journey investor. Their working relationship predates Siggy, as does their experience getting care out of the traditional office and into people's lives.

The company starts with an AI conversation that collects a patient's history. A licensed clinician reviews the information and makes the diagnosis and treatment decisions. Daily check-ins then gather sleep, mood, medication and physical wellbeing between appointments.

Those responses help produce the Siggy Score, a number out of 100 measured against the patient's own baseline. Siggy describes it as a directional measure, not a diagnosis. Changes can be flagged for the clinician to review, carrying the context that a brief appointment can struggle to recover from memory.

CTO Jake Bourke brings engineering experience from Coinbase and SimpliSafe, according to the company. Daniel Montville, MD, is CMO. That pairing puts the software and clinical responsibilities beside each other, where this service will have to keep them.

Albert Wenger, Immad Akhund and Toyin Ajayi through Coalition Operators are among the backers, alongside PsyMed Ventures, Mystic Ventures and Gokul Rajaram. The financing will support clinician and engineer hiring, software development and regulatory work, the founders told Crunchbase News.

Siggy says it accepts insurance across all 50 states and will remain free for veterans. Actual coverage still depends on the patient's plan and provider availability. Accepting insurance makes access part of the operating model, with the clinical staffing and administration that come with it.

For a patient, a daily check-in is a small request. For Siggy, it creates a growing responsibility to turn what people share into something the care team can review and use. The next day's account of poor sleep will arrive whether or not the product team has finished its next release.

SoftBank / ABB Robotics

A factory buying an ABB robot is making a decision that can outlast the deal to sell its maker. The machine needs software, service and somebody responsible for keeping the relationship working.

That helps explain the difficulty now facing SoftBank Group's proposed $5.375B purchase of ABB Robotics. China has prohibited the acquisition of the robotics business in China, according to updates from both companies. SoftBank received the notification on November 4; ABB disclosed the development on November 5, followed by SoftBank on November 6.

The companies say discussions continue. Neither update announces an agreed replacement structure, a revised price or the end of the global transaction. The geography in that disclosure matters to anybody trying to understand what SoftBank might eventually own.

Masayoshi Son, SoftBank Group's founder, Chairman & CEO, wanted an industrial platform with established technology, sales channels and customer relationships. ABB Robotics offered a route into factories already buying automation, alongside the AI capabilities SoftBank wanted to bring into the business.

ABB CEO Morten Wierod had chosen a sale over the earlier plan to list the division separately. At signing in October 2025, ABB described a business with approximately 7,000 employees and $2.3B in 2024 revenue. Those are historical figures, but they explain the scale of the operating responsibility attached to the purchase.

China sits inside that responsibility. ABB's July 2025 robot launches were manufactured at its Shanghai Mega Factory, with OmniCore connecting robot control to AI, sensors and computing. The local footprint helps serve the customers who made the business attractive in the first place.

Marc Segura, President of ABB Robotics, is also developing a business already moving toward physical AI. Its October 2026 application launch described tools for training and deploying AI-enabled robotic work. The product direction exists while the ownership discussion remains unsettled.

For an industrial customer, those two conversations eventually meet in a purchase order. Who supports the controller? Where does the next product investment land? How does a global supplier keep responsibility clear across a changing ownership map? Those are operating questions this transaction now carries into the negotiation.

SoftBank and ABB still have to establish a structure they can complete, with the factories and customer relationships they intend to keep connected inside it.

Atmospheric AI

A supplier asks for another $730 per tonne. The buyer needs to know how much of that increase belongs to the factory making the material.

Atmospheric AI describes a manufacturer facing exactly that proposal during the Hormuz disruption. Its calculation put the underlying manufacturing-cost increase at about $120 per tonne. That gave the sourcing team something useful to take back into the negotiation: an explanation of the increase it could defend.

Those are company-reported figures from 1 customer case, with no disclosed final settlement. The distinction matters when the product is being sold on the quality of its evidence.

Co-founders Roee Goldberg, CEO, and Toby Darbyshire are building around that purchasing problem. London-based Atmospheric AI has raised a $10.1M Seed round led by DBL Partners, with returning support including RAISE Ventures, Broadscale, tiny.vc and Anamcara. Norrsken Evolve also confirmed it followed on.

The company's November 5 announcement rounds the amount to $10M; its site banner and investor list give $10.1M. DBL's Vinnie Caruso joins the board.

Atmospheric AI starts with chemical engineering and plant economics, connecting production facilities and the routes between them. It says it runs around 50,000 facility models. The purpose is to estimate cost, carbon and supply risk without waiting for suppliers to open their operating books.

A procurement team already knows the quote. The value here is being able to ask which feedstock, process or route explains it, and whether another source changes the economics. That puts a supplier's explanation under more scrutiny before a buyer commits to the next order.

Founding CTO Rob McInerney leads the technical side. Dr Torsten Lichtenau, Founding CCO, brings 22 years at Bain & Company, including global carbon-transition leadership. Getting that engineering into a purchasing decision gives the commercial role plenty to do.

Haleon is a named customer relationship in the company's announcement. The funding is intended to extend work beyond plastics into chemicals, paper and metals, while deepening collaboration with an initial group of around 100 manufacturers.

Each new material takes Atmospheric AI into another set of plants, production assumptions and supplier conversations. The people buying it still have a price to agree, with a model they can now ask to explain its working.

Aulis Capital

Nisa Leung spent years building a healthcare investment practice inside Qiming Venture Partners. At Aulis Capital, she is putting that experience behind a new firm's own decisions about which science gets financed, and how it reaches patients across borders.

Aulis Capital has completed the final close of its inaugural Aulis Capital Fund I, L.P., with $200M in commitments. The mandate covers early- and growth-stage life sciences and healthcare companies. BioCentury reports offices in Hong Kong and California, giving the firm's global ambition a practical geography.

The interesting part sits inside Aulis's description of its work: connecting global-minded companies with Asia's engineering and clinical development strengths. For a healthcare founder, that relationship can touch the development plan itself. Where the work happens, which partners carry it forward, and what evidence travels with it all belong in the financing conversation.

Aulis is arriving with a portfolio relationship already underway. EpiBiologics named the firm among the investors in its January 2026 $107M Series B, and named Nisa Leung as an incoming board observer. The financing brought Aulis alongside specialist and pharmaceutical investors around a company developing antibodies designed to remove disease-driving proteins outside cells.

By April, EpiBiologics reported dosing the first patient in its global Phase 1 study of EPI-326. Its announcement described US enrollment and planned sites in Asia-Pacific, including South Korea. That is a concrete example of the international development work a healthcare investor may need to understand long before a therapy has an approved label.

Franck Le Deu, a former McKinsey partner, is also a Venture Partner at Aulis. Scientific judgment and company-building experience have different jobs here: understanding a promising mechanism, helping a team organize its development, and keeping the commercial destination in view as new evidence arrives.

The $200M represents commitments to the fund. Aulis has not disclosed the LP roster or how much of Fund I has been deployed, and the announcement gives no allocation by geography. Those details stay open rather than turning into a fictional deployment plan.

For Nisa Leung, the healthcare work continues through a new institution. For the scientists working with Aulis, the relationship will take shape through decisions about development partners, clinical programmes and the next body of evidence their companies need to produce.